Corporate Banner
Satellite Banner
qPCR
Scientific Community
 
Become a Member | Sign in
Home>News>This Article
  News
Return

Exosome Diagnostics Signs Agreement with Life Technologies

Published: Thursday, June 07, 2012
Last Updated: Thursday, June 07, 2012
Bookmark and Share
Exosome Diagnostics to use the Applied Biosystems® (ABI) 7500 Fast Dx Real-Time PCR Instrument for the Company's exosome biofluid in-vitro diagnostics oncology program.

Exosome Diagnostics plans to validate the ABI instrument platform with exosome biofluid RNA isolation technology kits in upcoming multi-center clinical trials in brain cancer and prostate cancer beginning in 2012.  The ABI 7500 Fast Dx Real-Time PCR Instrument is one of the most widely distributed PCR platforms in laboratories worldwide and is cleared by the Food and Drug Administration.

"Our product development strategy is to match our exosome-based diagnostics technology with the most technically appropriate and widely accepted platforms available," said David Okrongly, chief operating officer of Exosome Diagnostics.  "The ABI 7500 Fast Dx Real-Time PCR Instrument from Life Technologies combines state of the art quantitative PCR (qPCR) technology with broad market and regulatory acceptance, enabling physicians and laboratory customers to efficiently and accurately access diagnostic results."

Ron Andrews, president, Medical Sciences at Life Technologies added, "We are pleased to be partnered with Exosome Diagnostics as they develop their non-invasive cancer diagnostic programs. Our Medical Sciences strategy is focused on partnerships with emerging companies that have promising molecular diagnostic applications that enable the realization of personalized medicine in diseases like cancer."

Exosome Diagnostics is developing a series of urine and blood-based molecular diagnostic tests for use in cancer detection and monitoring.  Exosome Diagnostics' technology provides the ability to isolate a highly pure, stable preparation of ribonucleic acids from biofluids for analysis on existing analytical platforms such as qPCR and next-generation sequencing.  The Company is currently in the process of partnering with various manufacturing groups to provide branded, OEM in-vitro diagnostic solutions for regulatory approval and use in the Company's GLP CLIA-certified laboratory.

"This agreement with Life Technologies continues our pursuit of best-in-class partnerships that include the Prostate Cancer Foundation, Accelerate Brain Cancer Cure and the broad group of leading clinical investigators now collaborating on exosome technology," said James McCullough, chief executive officer of Exosome Diagnostics. "Life Technologies is leading the way in personalized medicine and provides us with the type of customer service and robust technology that are pre-requisites to the successful launch of innovative molecular diagnostics."


Further Information

Join For Free

Access to this exclusive content is for Technology Networks Premium members only.

Join Technology Networks Premium for free access to:

  • Exclusive articles
  • Presentations from international conferences
  • Over 3,500+ scientific posters on ePosters
  • More than 5,000+ scientific videos on LabTube
  • 35 community eNewsletters


Sign In



Forgotten your details? Click Here
If you are not a member you can join here

*Please note: By logging into TechnologyNetworks.com you agree to accept the use of cookies. To find out more about the cookies we use and how to delete them, see our privacy policy.


Scientific News
Analysing 10,000 Cells Simultaneously
New techniquethat traps 10,000 cells on a single chip has potential for cancer screening for individuals.
$1M NIH Grant to Refine PCR Based Cancer Test
Researchers at Cornell University, Weill Cornell Medicine, the University of California, San Francisco, and the Infectious Diseases Institute in Kampala, Uganda, recieve a four-year, $1 million grant to hone technology for a quick, in-the-field diagnosis of Kaposi's sarcoma — a cancer frequently related to HIV infections.
Genetic Tug of War Before Cells Decide Fate
Researchers report that as developing blood cells are triggered by genetic signals firing on and off, a 'tug of war' occurs.
Linkage Biosciences Awarded NHS Contract
Comapny announces that it has been awarded a four-year contract by NHS Blood and Transplant (NHSBT) in the UK for implementation of the LinkSeq™ Real-Time PCR HLA typing product.
Understanding Tumor Evolution
Study provides insight into tumor evolution; may point to improved diagnosis and treatment.
Frankfurter Fraud: Finding Out What’s In Your Hot Dog
Scientists have developed a technique to test the meat content of Frankfurters.
How Cloud Connectivity Can Combat the Reproducibility Crisis
This infographic explains the reproducibility crisis, and how cloud connectivity can help overcome this problem.
Keeping Cells in Shape to Fight Sepsis
Boosting levels of a protein that controls the shape and activity of a crucial group of white blood cells improves survival and recovery chances during sepsis.
This 3D Printer Can Detect Infectious Diseases
Researchers at AI Biosciences, Inc. have repurposed 3D printers into machines capable of performing sample preparation and DNA amplification.
Natera, UCSF Announce Collaboration
Joint research program to study DNA markers of kidney transplant rejection.

SELECTBIO Market Reports
Go to LabTube
Go to eposters
 
Access to the latest scientific news
Exclusive articles
Upload and share your posters on ePosters
Latest presentations and webinars
View a library of 1,800+ scientific and medical posters
3,500+ scientific and medical posters
A library of 2,500+ scientific videos on LabTube
5,000+ scientific videos
Close
Premium CrownJOIN TECHNOLOGY NETWORKS PREMIUM FOR FREE!